Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BARICITINIB Cause C-reactive protein increased? 33 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 33 reports of C-reactive protein increased have been filed in association with BARICITINIB (Olumiant). This represents 0.4% of all adverse event reports for BARICITINIB.

33
Reports of C-reactive protein increased with BARICITINIB
0.4%
of all BARICITINIB reports
1
Deaths
12
Hospitalizations

How Dangerous Is C-reactive protein increased From BARICITINIB?

Of the 33 reports, 1 (3.0%) resulted in death, 12 (36.4%) required hospitalization, and 4 (12.1%) were considered life-threatening.

Is C-reactive protein increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BARICITINIB. However, 33 reports have been filed with the FAERS database.

What Other Side Effects Does BARICITINIB Cause?

Drug ineffective (569) Off label use (479) Covid-19 (347) Pulmonary embolism (288) Rheumatoid arthritis (284) Headache (216) Herpes zoster (216) Pneumonia (216) Death (206) Deep vein thrombosis (201)

What Other Drugs Cause C-reactive protein increased?

METHOTREXATE (5,999) ADALIMUMAB (4,579) RITUXIMAB (4,060) ETANERCEPT (3,922) TOCILIZUMAB (3,719) INFLIXIMAB (3,621) LEFLUNOMIDE (3,574) HYDROXYCHLOROQUINE (3,552) ABATACEPT (3,451) SULFASALAZINE (3,096)

Which BARICITINIB Alternatives Have Lower C-reactive protein increased Risk?

BARICITINIB vs BARIUM BARICITINIB vs BARNIDIPINE BARICITINIB vs BASILIXIMAB BARICITINIB vs BAYER GENUINE ASPIRIN ORIGINAL STRENGTH BARICITINIB vs BAZEDOXIFENE\ESTROGENS, CONJUGATED

Related Pages

BARICITINIB Full Profile All C-reactive protein increased Reports All Drugs Causing C-reactive protein increased BARICITINIB Demographics